Phaseline

Targets › SLC39A6

SLC39A6 (Zinc transporter ZIP6): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Sep 2030.

Zinc-influx transporter which plays a role in zinc homeostasis and in the induction of epithelial-to-mesenchymal transition (EMT). When associated with SLC39A10, the heterodimer formed by SLC39A10 and SLC39A6 mediates cellular zinc uptake to trigger cells to undergo epithelial- to-mesenchymal transition (EMT). (UniProt, Q13433)

Open in Phaseline: the race on SLC39A6, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
RocheLadiratuzumab Vedotin
Tubulin inhibitor; Zinc transporter ZIP6 binding agent
Tubulin, SLC39A6Phase 1Metastatic Breast CancerSep 2030

Conditions

Metastatic Breast Cancer (1)

Modalities

mixed (1)

Companies

Roche (1)

Related targets

Tubulin (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.